Is Regorafenib a targeted drug?

Regorafenib (Regorafenib) is a targeted therapy called a multikinase inhibitor. Kinases are proteins on or near the cell surface that carry important signals to the cell's control centers. Regofenib blocks several kinase proteins that either help tumor cells grow or help form new blood vessels to nourish tumors. Blocking these proteins can help stop the growth of cancer cells.

RegofenibThis drug is used to treat advanced colorectal cancer, often when other drugs are no longer effective. It is taken as a pill. After the right trials, two phase 3 trials showed benefit compared with placebo. The dose of regorafenib was 150 or 160 mg/d during the first 3 weeks of each 4-week cycle. Common side effects include fatigue, rash, hand-foot syndrome (redness and inflammation of the hands and feet), diarrhea, high blood pressure, weight loss and abdominal pain. Less common but more serious side effects include severe bleeding or perforation in the stomach or intestines.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).